First Time Loading...

Enanta Pharmaceuticals Inc
NASDAQ:ENTA

Watchlist Manager
Enanta Pharmaceuticals Inc Logo
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
Watchlist
Price: 15.17 USD 9.06% Market Closed
Updated: May 6, 2024

Enanta Pharmaceuticals Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Enanta Pharmaceuticals Inc
Revenue Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Enanta Pharmaceuticals Inc
NASDAQ:ENTA
Revenue
$73.6m
CAGR 3-Years
-10%
CAGR 5-Years
-21%
CAGR 10-Years
31%
Abbvie Inc
NYSE:ABBV
Revenue
$54.3B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$27.5B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Revenue
$28.2B
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$9.9B
CAGR 3-Years
17%
CAGR 5-Years
26%
CAGR 10-Years
23%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.1B
CAGR 3-Years
16%
CAGR 5-Years
14%
CAGR 10-Years
20%

Enanta Pharmaceuticals Inc
Revenue Breakdown

Breakdown by Geography
Enanta Pharmaceuticals Inc

Not Available

Breakdown by Segments
Enanta Pharmaceuticals Inc

Total Revenue: 79.2m USD
100%
Royalty: 78.2m USD
98.7%
License: 1m USD
1.3%

See Also

What is Enanta Pharmaceuticals Inc's Revenue?
Revenue
73.6m USD

Based on the financial report for Dec 31, 2023, Enanta Pharmaceuticals Inc's Revenue amounts to 73.6m USD.

What is Enanta Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
31%

Over the last year, the Revenue growth was -10%. The average annual Revenue growth rates for Enanta Pharmaceuticals Inc have been -10% over the past three years , -21% over the past five years , and 31% over the past ten years .